---
title: "Berenberg Bank Sticks to Its Hold Rating for Symrise (0G6T)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278749811.md"
description: "Berenberg Bank has maintained a Hold rating for Symrise (0G6T) with a price target of €81.20, as reported by analyst Matthew Abraham. He focuses on the Consumer Defensive sector and has an average return of 1.9% with a 51.39% success rate. Additionally, Barclays also issued a Hold rating for Symrise, while J.P. Morgan maintained a Buy rating on the same day."
datetime: "2026-03-11T14:06:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278749811.md)
  - [en](https://longbridge.com/en/news/278749811.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278749811.md)
---

# Berenberg Bank Sticks to Its Hold Rating for Symrise (0G6T)

In a report released today, Matthew Abraham from Berenberg Bank maintained a Hold rating on Symrise, with a price target of €81.20.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Abraham covers the Consumer Defensive sector, focusing on stocks such as Chocoladefabriken Lindt & Spruengli AG, Mondelez International, and Nestlé SA. According to TipRanks, Abraham has an average return of 1.9% and a 51.39% success rate on recommended stocks.

In addition to Berenberg Bank, Symrise also received a Hold from Barclays’s Alex Sloane in a report issued yesterday. However, on the same day, J.P. Morgan maintained a Buy rating on Symrise (LSE: 0G6T).

### Related Stocks

- [SY1.DE](https://longbridge.com/en/quote/SY1.DE.md)
- [SYIEY.US](https://longbridge.com/en/quote/SYIEY.US.md)

## Related News & Research

- [Symrise invests EUR 25 million to expand Holzminden logistics center](https://longbridge.com/en/news/287229512.md)
- [Berenberg Bank Sticks to Its Hold Rating for Symrise (0G6T)](https://longbridge.com/en/news/272983792.md)
- [Nano4Imaging tools enable MRI-guided pulmonary artery stenting without X-rays, study shows](https://longbridge.com/en/news/287229490.md)
- [Immix Biopharma NEXICART-2 interim: 95% CR rate (19/20) as all MRD-negative patients convert](https://longbridge.com/en/news/287198562.md)
- [Should You Think About Buying Synergie SE (EPA:SDG) Now?](https://longbridge.com/en/news/287156751.md)